Corrigendum to "A six-weekly (Q6W) dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation" [Eur J Canc 131 (2020) 68-75]

Affiliations

¹ Quantitative Pharmacology and Pharmacometrics; Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co., Inc., Kenilworth, NJ, USA.
² Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.
³ University of Toronto, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
⁴ Oncology Early Development, Merck & Co., Inc., Kenilworth, NJ, USA.
⁵ Clinical Safety and Risk Management, Merck & Co., Inc., Kenilworth, NJ, USA.
⁶ Quantitative Pharmacology and Pharmacometrics; Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co., Inc., Kenilworth, NJ, USA. Electronic address: lokesh.jain@merck.com.

Published Erratum

Mallika Lala et al. Eur J Cancer. 2021 Feb.

. 2021 Feb:144:400.

doi: 10.1016/j.ejca.2020.12.006. Epub 2021 Jan 4.

¹ Quantitative Pharmacology and Pharmacometrics; Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co., Inc., Kenilworth, NJ, USA.
² Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.
³ University of Toronto, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
⁴ Oncology Early Development, Merck & Co., Inc., Kenilworth, NJ, USA.
⁵ Clinical Safety and Risk Management, Merck & Co., Inc., Kenilworth, NJ, USA.
⁶ Quantitative Pharmacology and Pharmacometrics; Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co., Inc., Kenilworth, NJ, USA. Electronic address: lokesh.jain@merck.com.

No abstract available

Erratum for

A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation.
Lala M, Li TR, de Alwis DP, Sinha V, Mayawala K, Yamamoto N, Siu LL, Chartash E, Aboshady H, Jain L. Lala M, et al. Eur J Cancer. 2020 May;131:68-75. doi: 10.1016/j.ejca.2020.02.016. Epub 2020 Apr 15. Eur J Cancer. 2020. PMID: 32305010